Published in J Clin Oncol on June 15, 2004
The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol (2014) 1.70
The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions. Support Care Cancer (2006) 1.57
Complementary and alternative medicine in children. Eur J Pediatr (2012) 1.38
Polypharmacy in older adults with cancer. Oncologist (2010) 1.23
Pharmacokinetic interaction between the flavonoid luteolin and gamma-hydroxybutyrate in rats: potential involvement of monocarboxylate transporters. AAPS J (2008) 0.99
Complementary and alternative medicine: use and disclosure in radiation oncology community practice. Support Care Cancer (2010) 0.98
The use of dietary supplements in a community hospital comprehensive cancer center: implications for conventional cancer care. Support Care Cancer (2005) 0.96
Therapeutic uses and pharmacological properties of garlic, shallot, and their biologically active compounds. Iran J Basic Med Sci (2013) 0.92
The status of complementary therapy services in Canadian palliative care settings. Support Care Cancer (2007) 0.92
Herbal medicine and acupuncture for breast cancer palliative care and adjuvant therapy. Evid Based Complement Alternat Med (2013) 0.90
Structure-activity relationship and substrate-dependent phenomena in effects of ginsenosides on activities of drug-metabolizing P450 enzymes. PLoS One (2008) 0.90
Therapeutic applications of herbal medicines for cancer patients. Evid Based Complement Alternat Med (2013) 0.90
Echinacea: a miracle herb against aging and cancer? Evidence in vivo in mice. Evid Based Complement Alternat Med (2005) 0.88
Patient-physician communication about complementary and alternative medicine in a radiation oncology setting. Int J Radiat Oncol Biol Phys (2012) 0.86
Herbal Insomnia Medications that Target GABAergic Systems: A Review of the Psychopharmacological Evidence. Curr Neuropharmacol (2014) 0.84
Ginkgo biloba for the treatment of vitilgo vulgaris: an open label pilot clinical trial. BMC Complement Altern Med (2011) 0.83
Coprescription of Chinese Herbal Medicine and Western Medications among Prostate Cancer Patients: A Population-Based Study in Taiwan. Evid Based Complement Alternat Med (2011) 0.83
Drug interactions in childhood cancer. Lancet Oncol (2010) 0.83
Therapeutic Effectiveness of Anticancer Phytochemicals on Cancer Stem Cells. Toxins (Basel) (2016) 0.82
National survey of US oncologists' knowledge, attitudes, and practice patterns regarding herb and supplement use by patients with cancer. J Clin Oncol (2014) 0.82
Use of prescription and nonprescription medications and supplements by cancer patients during chemotherapy: questionnaire validation. J Oncol Pharm Pract (2008) 0.81
Dietary supplement use among elderly, long-term cancer survivors. J Cancer Surviv (2008) 0.81
Chloroform Fraction of Centratherum anthelminticum (L.) Seed Inhibits Tumor Necrosis Factor Alpha and Exhibits Pleotropic Bioactivities: Inhibitory Role in Human Tumor Cells. Evid Based Complement Alternat Med (2012) 0.81
An onco-informatics database for anticancer drug interactions with complementary and alternative medicines used in cancer treatment and supportive care: an overview of the OncoRx project. Support Care Cancer (2009) 0.81
Enhanced radiation sensitivity and radiation recall dermatitis (RRD) after hypericin therapy -- case report and review of literature. Radiat Oncol (2006) 0.81
Identifying unproven cancer treatments on the health web: addressing accuracy, generalizability and scalability. Stud Health Technol Inform (2013) 0.80
A survey on herbal management of hepatocellular carcinoma. World J Hepatol (2011) 0.80
Ginseng and anticancer drug combination to improve cancer chemotherapy: a critical review. Evid Based Complement Alternat Med (2014) 0.80
Bridging cross-cultural gaps: monitoring herbal use during chemotherapy in patients referred to integrative medicine consultation in Israel. Support Care Cancer (2014) 0.79
Use of complementary medications among older adults with cancer. Cancer (2012) 0.79
Does perceived control predict Complementary and Alternative Medicine (CAM) use among patients with lung cancer? A cross-sectional survey. Support Care Cancer (2014) 0.79
Use of complementary and alternative medicine by patients with cancer. Prim Care Companion CNS Disord (2011) 0.79
Understanding CAM Natural Health Products: Implications of Use Among Cancer Patients and Survivors. J Adv Pract Oncol (2013) 0.79
Preventive effect of chrysin on bleomycin-induced lung fibrosis in rats. Inflammation (2014) 0.79
A phosphotyrosine switch regulates organic cation transporters. Nat Commun (2016) 0.78
Optimizing chemotherapy: concomitant medication lists. Clin Pharmacol Ther (2010) 0.78
Perceptions about complementary and alternative medicine use among Chinese immigrant parents of children with cancer. Support Care Cancer (2011) 0.78
Pungent ginger components modulates human cytochrome P450 enzymes in vitro. Acta Pharmacol Sin (2013) 0.78
Effect of age on drug metabolism in women with breast cancer. Expert Opin Drug Metab Toxicol (2015) 0.78
Effects of allicin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes. Eur J Clin Pharmacol (2009) 0.78
Dietary supplement use among participants of a databank and biorepository at a comprehensive cancer centre. Public Health Nutr (2014) 0.77
A Methodological Framework for Evaluating the Evidence for Complementary and Alternative Medicine (CAM) for Cancer. Cancers (Basel) (2011) 0.77
The effect of grape seed extract on the pharmacokinetics of dextromethorphan in healthy volunteers. Eur J Clin Pharmacol (2013) 0.77
The Peter Brojde lung cancer centre: a model of integrative practice. Curr Oncol (2012) 0.77
The use of complementary and alternative medicine after the completion of hospital treatment for colorectal cancer: findings from a questionnaire study in Denmark. BMC Complement Altern Med (2014) 0.77
Complementary and alternative medicine: a survey of its use in pediatric oncology. Evid Based Complement Alternat Med (2013) 0.76
Variable inhibitory effect of herbal supplements of different brands on human P450 CYP1A2. EXCLI J (2012) 0.76
SH003 induces apoptosis of DU145 prostate cancer cells by inhibiting ERK-involved pathway. BMC Complement Altern Med (2016) 0.75
National survey of China's oncologists' knowledge, attitudes, and clinical practice patterns on complementary and alternative medicine. Oncotarget (2017) 0.75
Medication use by middle-aged and older participants of an exercise study: results from the Brain in Motion study. BMC Complement Altern Med (2017) 0.75
Investigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancer. Springerplus (2013) 0.75
Cytochrome P450 enzyme mediated herbal drug interactions (Part 2). EXCLI J (2014) 0.75
AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011. Breast Care (Basel) (2011) 0.75
Crude aqueous extracts of Pluchea indica (L.) Less. inhibit proliferation and migration of cancer cells through induction of p53-dependent cell death. BMC Complement Altern Med (2012) 0.75
The influence of standardized Valeriana officinalis extract on the CYP3A1 gene expression by nuclear receptors in in vivo model. Biomed Res Int (2014) 0.75
Herb-drug pharmacokinetic interaction of a traditional chinese medicine jia-wei-xiao-yao-san with 5-Fluorouracil in the blood and brain of rat using microdialysis. Evid Based Complement Alternat Med (2015) 0.75
Influence of First-Line Antibiotics on the Antibacterial Activities of Acetone Stem Bark Extract of Acacia mearnsii De Wild. against Drug-Resistant Bacterial Isolates. Evid Based Complement Alternat Med (2014) 0.75
How are Interactions Taken into Account in Studies on Conventional and Complementary Therapies for Breast Cancer Patients with Menopausal Complaints? Geburtshilfe Frauenheilkd (2012) 0.75
Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. Leuk Lymphoma (2016) 0.75
Can ginseng alleviate cancer-related fatigue? J Adv Pract Oncol (2013) 0.75
A pilot study of website information regarding aromatase inhibitors: dietary supplement interactions. J Altern Complement Med (2011) 0.75
Effects of Ginkgo biloba on chemically-induced mammary tumors in rats receiving tamoxifen. BMC Complement Altern Med (2013) 0.75
Traditional Herbal Formulas to as Treatments for Musculoskeletal Disorders: Their Inhibitory Effects on the Activities of Human Microsomal Cytochrome P450s and UDP-glucuronosyltransferases. Pharmacogn Mag (2016) 0.75
Suppression of Nrf2 Activity by Chestnut Leaf Extract Increases Chemosensitivity of Breast Cancer Stem Cells to Paclitaxel. Nutrients (2017) 0.75
Polypharmacy in the Geriatric Oncology Population. Curr Oncol Rep (2017) 0.75
Integration of complementary medicine in supportive cancer care: survey of health-care providers' perspectives from 16 countries in the Middle East. Support Care Cancer (2015) 0.75
Expectations from an integrative medicine consultation in breast cancer care: a registry protocol-based study. Support Care Cancer (2014) 0.75
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res (2002) 4.90
Pharmacy education: back to the basics? Pharmacotherapy (2003) 4.11
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol (2008) 3.32
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol (2004) 3.16
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol (2009) 3.13
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood (2011) 2.64
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res (2010) 2.45
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol (2005) 2.36
Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther (2005) 2.23
Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res (2007) 2.22
Thalidomide. Lancet (2004) 2.21
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood (2007) 2.15
Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2009) 2.06
Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin (2010) 1.98
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol (2008) 1.95
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res (2008) 1.95
Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol (2008) 1.91
Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proc Natl Acad Sci U S A (2009) 1.89
Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res (2005) 1.88
A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res (2008) 1.87
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol (2004) 1.85
Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res (2005) 1.84
Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol (2005) 1.81
Validation of analytic methods for biomarkers used in drug development. Clin Cancer Res (2008) 1.73
Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. J Clin Oncol (2002) 1.71
A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol (2002) 1.68
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 1.65
A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clin Cancer Res (2012) 1.64
Drug interactions in cancer therapy. Nat Rev Cancer (2006) 1.62
Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res (2006) 1.60
The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther (2009) 1.57
Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Updat (2003) 1.54
Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. Cancer Res (2008) 1.53
Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. Curr Neuropharmacol (2006) 1.53
Flavopiridol inversely affects p21(WAF1/CIP1) and p53 and protects p21-sensitive cells from paclitaxel. Cancer Biol Ther (2002) 1.50
Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res (2008) 1.48
Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. BJU Int (2013) 1.47
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. Eur Urol (2007) 1.46
Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res (2009) 1.46
Epidithiodiketopiperazines block the interaction between hypoxia-inducible factor-1alpha (HIF-1alpha) and p300 by a zinc ejection mechanism. J Biol Chem (2009) 1.44
Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy. J Clin Endocrinol Metab (2010) 1.44
A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU Int (2008) 1.41
Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol (2002) 1.40
Lack of ABC transporter autoinduction in mice following long-term exposure to imatinib. Cancer Biol Ther (2007) 1.40
Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. Mol Cancer Res (2006) 1.40
2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy (2003) 1.40
Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood (2011) 1.39
Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma. J Pharm Biomed Anal (2008) 1.39
A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. J Urol (2005) 1.38
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int (2009) 1.37
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur J Cancer (2009) 1.36
Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev Anticancer Ther (2010) 1.34
Clinical and molecular responses in lung cancer patients receiving Romidepsin. Clin Cancer Res (2008) 1.34
Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther (2006) 1.33
A retrospective study of the time to clinical endpoints for advanced prostate cancer. BJU Int (2005) 1.33
Expression of OATP family members in hormone-related cancers: potential markers of progression. PLoS One (2011) 1.32
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst (2010) 1.30
Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin Drug Metab Toxicol (2005) 1.29
Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin Cancer Res (2007) 1.27
Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol (2003) 1.26
Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice. Clin Cancer Res (2004) 1.25
Determination of midazolam in human plasma by liquid chromatography with mass-spectrometric detection. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 1.25
Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro (2005) 1.24
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest (2009) 1.23
Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer (2006) 1.23
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J Exp Clin Cancer Res (2010) 1.23
Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res (2002) 1.23
Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors. Clin Cancer Res (2011) 1.22
ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin Cancer Res (2008) 1.22
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. Clin Cancer Res (2012) 1.21
Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. J Clin Oncol (2004) 1.21
Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br J Clin Pharmacol (2011) 1.20
A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clin Cancer Res (2011) 1.20
Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel. Clin Cancer Res (2006) 1.19
The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenet Genomics (2013) 1.19
Safety and feasibility of long-term intravenous sodium nitrite infusion in healthy volunteers. PLoS One (2011) 1.19
Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics (2005) 1.18
The quantification of PSA mRNA copies in pathologically normal pelvic lymph nodes is a viable prognostic indicator. Cancer Biol Ther (2006) 1.17
Transition of a clinical trial into translational research: the prostate cancer prevention trial experience. Cancer Prev Res (Phila) (2010) 1.17
Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res (2009) 1.17
Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol (2002) 1.16
Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer Biol Ther (2005) 1.15
Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform. Pharmacogenomics (2010) 1.15
A working group classification of focal prostate atrophy lesions. Am J Surg Pathol (2006) 1.13
Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 1.13
Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Mol Cancer Ther (2008) 1.13
Review of UCN-01 development: a lesson in the importance of clinical pharmacology. J Clin Pharmacol (2005) 1.12
Phase I study of oral lenalidomide in patients with refractory metastatic cancer. J Clin Pharmacol (2009) 1.11
Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst (2004) 1.10
Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 1.09
CYP2D6 polymorphisms and the impact on tamoxifen therapy. J Pharm Sci (2007) 1.09
A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. Clin Cancer Res (2007) 1.09
Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res (2002) 1.09
Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. Pharmacogenomics (2007) 1.09